Long-Term Outcomes in Real Life of Lumacaftor–Ivacaftor Treatment in Adolescents With Cystic Fibrosis

Background: The combination of the CFTR corrector lumacaftor (LUM) and potentiator ivacaftor (IVA) has been labeled in France since 2015 for F508del homozygote cystic fibrosis (CF) patients over 12 years. In this real-life study, we aimed (i) to compare the changes in lung function, clinical (e.g.,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bui, Stéphanie, Masson, Alexandra, Enaud, Raphaël, Roditis, Léa, Dournes, Gaël, Galode, François, Collet, Cyrielle, Mas, Emmanuel, Languepin, Jeanne, Fayon, Michael, Beaufils, Fabien, Mittaine, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634876/
https://www.ncbi.nlm.nih.gov/pubmed/34869102
http://dx.doi.org/10.3389/fped.2021.744705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634876/
https://www.ncbi.nlm.nih.gov/pubmed/34869102
http://dx.doi.org/10.3389/fped.2021.744705

Ejemplares similares